newsfilter
← Latest News
GlobeNewswire·

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to